Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bortezomib as consolidation therapy in patients aged 60 years and younger with multiple myeloma

Trial Profile

Bortezomib as consolidation therapy in patients aged 60 years and younger with multiple myeloma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Feb 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bortezomib (Primary)
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Sponsors Janssen-Cilag
  • Most Recent Events

    • 06 Dec 2016 Results of pooled analysis of two trials (NCT00416273 and NCT00416208) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 14 Jun 2015 Results of pooled analysis of MMY3012 and MMY3013 trials presented at the 20th Congress of the European Haematology Association.
    • 02 Jun 2015 Results of pooled analysis of MMY3012 and MMY3013 trials presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top